Why States' 'Netflix Model' Prescription Drug Arrangements Are No Silver Bullet
Despite the buzz and catchy notion that subscription models are “Netflix for drugs,” it's hard to come up with a theoretical case that supports subscription models over traditional price negotiation between payers and manufacturers over a per-dose or per-unit price.
Jul 1, 2020 Health Affairs Blog
Coronavirus Outbreak Intensifies: Q&A with RAND Experts
Cases of the coronavirus have now spread to several dozens of countries, infecting thousands and thousands of people across the globe. With concerns about the disease rising, we asked a group of RAND researchers to answer a wide range of questions about the crisis.
Mar 5, 2020
The Promise and Peril of Offshoring Prescription Drug Pricing
Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.
Sep 16, 2019 The Hill
Price-Fixing Case Reveals Vulnerability of Generic Drug Policies
A massive lawsuit filed by 44 states accuses 20 major drug makers of colluding to inflate prices on more than 100 generic drugs, including HIV, cancer, and depression treatments. If these allegations are true, then this isn't just a violation of antitrust law. It's a betrayal of the policies that created and defended the entire generic drug industry.
Jul 15, 2019 The Health Care Blog
Covering Emergency Care for Young Adults: Is the ACA Doing Its Job?
The dependent coverage provision of the Affordable Care Act is working as intended, say Andrew Mulcahy and Katherine Harris. In 2011, it spared individuals and hospitals from $147 million in emergency room costs.
Jun 5, 2013